Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000713796 | SCV000844432 | likely pathogenic | not provided | 2020-09-28 | criteria provided, single submitter | clinical testing | The frequency of this variant in the general population is consistent with pathogenicity (http://gnomad.broadinstitute.org). This variant has been identified in at least one individual with clinical features associated with this gene. Assessment of experimental evidence suggests this variant results in abnormal protein function. The variant impaired the DNA binding and transactivation activity of the protein (PMID: 27899486). The variant is located in a region that is considered important for protein function and/or structure. |
Clinical Genomics, |
RCV002463736 | SCV002604889 | uncertain significance | Maturity onset diabetes mellitus in young | criteria provided, single submitter | research | Mutations in HNF1A gene can predispose to MODY3. It is associated with both micro and macrovascular complications of diabetes, especially cardiovascular complications. Associated with glucosuria. May respond well to sulfonylureas. However, more evidence is required to confer the association of this particular variant rs1288094664 with MODY3. | |
Fulgent Genetics, |
RCV002507251 | SCV002816602 | likely pathogenic | Diabetes mellitus type 1; Type 1 diabetes mellitus 20; Maturity-onset diabetes of the young type 3; Type 2 diabetes mellitus; Hepatic adenomas, familial; Nonpapillary renal cell carcinoma | 2022-02-18 | criteria provided, single submitter | clinical testing |